Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing
Published Time:
2025-01-22 17:49
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.
Dr. Gong Yanchun, Co-founder and CEO, stated: "Jiangsu Vcare has always adhered to the strategic layout of dual-wheel drive and coordinated development of its two core businesses: independent research and development of innovative drugs, and full-industry-chain CRO/CDMO services for pharmaceuticals.Three self-developed drug candidates have now entered confirmatory clinical studies, while our CRO/CDMO business continues rapid expansion with increasingly diversified service models. Our forward-looking strategic planning positions us to further solidify core competitiveness. With strong support from investors , we will break new ground, navigate market cycles, and achieve sustainable high-quality development."
Previous Page
Related News
04
2024
/
01
Recently, Jiangsu Vcare Pharmaceutical Technology Co., Ltd. (Jiangsu Vcare) completed the first patient enrollment in the pivotal Phase II clinical trial (Registration Number: CTR20201703) in China for its self-developed next-generation TRK inhibitor, VC004. This clinical trial aims to further evaluate the efficacy and safety of VC004 in treating patients with NTRK gene fusion mutations.
02
2024
/
01
Jiangsu Vcare Secures Over CNY 450 Million in Series C Funding
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C financing round, raising over CNY 450 million. The investment consortium included China Life Private Equity Investment, DYEE Capital, Hongyao Technology Capital, existing investor Nanjing Innovation Capital Group, and Hangzhou Huadian Investment.
13
2023
/
12
Jiangsu Vcare Approved to Establish "Provincial-Level Enterprise Technology Center"
Recently, the Jiangsu Provincial Department of Industry and Information Technology released the list of enterprises proposed for recognition as 2023 Provincial-Level Enterprise Technology Centers. Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) has been recognized as a"2023 Provincial-Level Enterprise Technology Center".
10
2023
/
11
Jiangsu Vcare's Next-Generation TRK Inhibitor VC004 Enters Pivotal Phase II Trial
Recently, the initiation of the pivotal Phase II trial for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 project was announced at its first center, the Cancer Hospital Chinese Academy of Medical Sciences. Subsequent recruitment will take place across nearly 30 clinical centers nationwide.
01
2023
/
11
Recently, the pivotal Phase II clinical study for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 for treating NTRK fusion-positive solid tumors was approved by the NMPA. This clinical study will further evaluate the efficacy and safety of VC004 in patients with NTRK fusion mutations. Upon success, Jiangsu Vcare plans to submit an NDA in China.
11
2023
/
08
Recently, the second-generation selective JAK1 inhibitor VC005 Topical Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), completed the first topical skin dosing in a patient with mild-to-moderate atopic dermatitis(AD).